Santa Monica, CA, July 24, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical technology
company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6
billion electrophysiology (EP) marketplace, was featured in The Silicon Review’s list of Top 50 Innovative Companies to Watch in
2018.
The Silicon Review garners more 160,000 unique visitors per month and appeals to business and technology
professionals. Featuring CEOs from groundbreaking companies, such as Daniel Springer of DocuSign, this Top 50 Innovative
Companies to Watch in 2018 list highlights individuals that are addressing market needs through providing unique
solutions.
“We are extremely pleased and honored to have our Company and CEO, Mr. Ken Londoner, featured in this prominent publication
highlighting the potential and innovation of the PURE EPTM System,” stated Mrs. Natasha Russkina, Vice President for
Business Development & Corporate Finance of BioSig Technologies, Inc. “Recognition for the innovative work that the Company is
conducting is reinforcing our belief that BioSig will continue to impact the disruptive bioelectronic medicine ecosystem.”
The Silicon Review’s dialog with Mr. Londoner displays his approach to developing a sustainable company with strategic financing
and excellent leadership. With the electrophysiology market expected to reach $4.73 billion by 2019, the innovative PURE
EPTM System will aim provide the solution to generating accurate clinical data through higher resolution and broader
dynamic ranges.
To view the interview with Ken Londoner and The Silicon Review, click the link below.
The Silicon Review Interview With Ken Londoner
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to
improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of
Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been
developed to address an unmet need in a large and growing market. The Company’s first product, PURE EP™ System, is a novel
cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during
procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to
improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the
PURE EP™ System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed
information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in
the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s
website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Russkina BioSig Technologies, Inc. VP Business Development & Corporate Finance nrusskina@biosigtech.com +41 (0) 76 823 7527
